AU
AU
CA
NZ
US
UK
Webinars
Kalkine Plus
Industries
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Stock Research
Our Product
Low-To-Medium Risk
High-Risk High-Reward
Diversified Themes Reports
Technical Analysis Reports
Market Capitalization
Blue Chip
Mid Cap
Small Cap
Model Portfolios
Value Model Portfolio
Growth Model Portfolio
Momentum Model Portfolio
Pricing
Low-To-Medium Risk
Inflation Report
US Dividend Income Report
Kalkine Resource Report
KALIN
Earnings Hunter Report
Real Estate Report
Healthcare Report
Gold Report
US Equities Report
Dividend Income Report
The Funds Report
Agriculture Report
High-Risk High-Reward
‘Stocks Under 20 cents’ Report
American Tech Report
Technology Report
Penny Stocks Report
Growth Report
Artificial Intelligence and Emerging Technologies Report
Diversified Themes Reports
Kalkine IPO Report
Global Big Money Report
Global Fully Charged Report
Global Green Energy Report
Market Event Report
Sector Report
Weekly Stock Market Digest
Kalkine Stocks Ranking Report
Low Carbon Research Report
Technical Analysis Reports
Bullish Chart Report
Cryptocurrency Report
US Technical Analysis Report
Global Commodity Technical Analysis Report
AU Technical Analysis Report
Meme Coin Report
About Us
Investing News
General News
Economic News
Market News
Currencies
Analyst Forecast
Commodities
Corporate News
General News
Politics
Organisations
By Industry
Financials
Industrials
Utilities
Mining & Materials
Healthcare
Real Estate
Consumer
Technology,Media & Telecommunications
Infrastructure
Energy
Services
Others
By Types
Blue Chip Stocks
Growth Stocks
Value Stocks
Penny Stocks
Dividend Stocks
Small Cap stocks
Mid Cap Stocks
Technical Analysis
IPO News
Discover More
Educational Topics
Personal Finance
Lifestyle
stocks
Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q4 Sales Targets, Stock Drops 12.1%
Fri 28 Feb 25, 09:02 AM | EODHD